IND Success Strategy: Building a High-Quality IND from Scratch with Strategic Gap Analysis
Learn how Veristat’s regulatory team helped our sponsor without internal expertise develop, compile, and submit a complete, FDA-compliant IND...
Extending our scientific depth across allergy, dermatology, ophthalmology, respiratory, women's health, and more.
There is much for companies to consider before submitting an investigational new drug (IND) application to FDA. Planning, collecting the appropriate data, and effectively communicating with regulatory bodies can all help companies overcome challenges in the pre-clinical stage of development and efficiently prepare for IND applications.
There is no single solution to a successful regulatory strategy and IND application. Companies that want to excel in the IND application process must have an integrated and expertly coordinated approach to IND planning and execution. With proper project and risk management as well as rapid decision-making, your company can prepare a quality and timely IND application.
Three of Veristat's Regulatory experts - Mara Holinger, Kevin Hennegan, and Erin Flynn - weigh in and share their thoughts on common IND misconceptions.
Read the full article to learn more about the following:
Explore related services:
Learn how Veristat’s regulatory team helped our sponsor without internal expertise develop, compile, and submit a complete, FDA-compliant IND...
Data Monitoring Committees (DMCs) play a vital role in clinical trials by providing independent oversight to ensure patient safety, maintain...
Discover how Veristat's expertise in IND submissions and strategic planning paved the way for a small-sized biotech company to advance into a Phase I...